Navigation Links
NYU Langone Medical Center researcher named Howard Hughes Investigator
Date:5/9/2013

NEW YORK, May 9, 2013 The Howard Hughes Medical Institute (HHMI) has announced the appointment of Evgeny Nudler, PhD, to the 2013 class of HHMI Investigators.The appointment ranks as one of the highest honors that can be bestowed on a biomedical research scientist. Dr. Nudler, the Julie Wilson Anderson Professor of Biochemistry in the Department of Biochemistry and Molecular Pharmacology at NYU Langone Medical Center, was selected among more than 1,200 applicants for his work on numerous biochemical frontiers, including the role of bacterial gases in antibiotic resistance and the interplay between RNA transcription and the cellular response to stress.

"The depth and breadth of Evgeny Nudler's research is absolutely remarkable," said Dafna Bar-Sagi, PhD, senior vice president and vice dean for science and chief scientific officer at NYU School of Medicine. "The five highly unique projects underway in his lab hold promise for a broad range of diseases, from cancer and heart disease to bacterial infections and Alzheimer's. His versatility and range are invaluable, and his selection as an HMMI Investigator is richly deserved."

Most recently, Dr. Nudler and his colleagues have discovered how the roundworm exploits bacteria within its gut to harness the life-extending benefits of nitric oxide, a gas implicated in a wide range of physiological functions from blood pressure to immune response in mammals. This finding could help unravel the mysteries of human longevity, as our cells may employ a similar biochemical mechanism.

Bacteria cells also exploit nitric oxide for their own purposes, Dr. Nudler has found. In a discovery that sheds light on antibacterial resistance, his team has revealed how the dangerous bacterial species Staphylococcus aureus and Bacillus anthracis manufacture nitric oxide and hydrogen sulfide to guard against oxidative stress and evade many different classes of antibiotics.

Among Dr. Nudler's other scientific contributions, his team was the first to discover bits of RNA present in all life forms that function as molecular circuits to control gene expression. These so-called "riboswitches" are now promising new targets for synthetic molecular switches and antimicrobial therapies. His lab has also developed a suite of biochemical tools to examine how RNA polymerase transcribes RNA from DNA. RNA polymerase is key enzyme of gene regulation and Nudler's work has explained how it moves along DNA, responds to regulatory signals and factors, and terminates transcription. Finally, Dr. Nudler's lab has identified the key biochemical components that allow cells to cope with high temperature and other types of stress that jeopardize the integrity of proteins. A better understanding of these components could lead to therapies that help repair damaged proteins related to cancer and neurodegenerative diseases such as Alzheimer's and Amyotrophic lateral sclerosis (ALS).


'/>"/>

Contact: Lisa Greiner
lisa.greiner@nyumc.org
212-404-3532
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related biology news :

1. St. Jude scientist named Howard Hughes Medical Institute investigator
2. Using bacteria-eaters to prevent infections on medical implant materials
3. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
4. BUSM study shows positive impact of mind-body course on well-being of medical students
5. Quest for edible malarial vaccine leads to other potential medical uses for algae
6. New cutting-edge cell research will lead to safer medical experiments on humans
7. PeerJ launches PeerJ PrePrints -- a preprint server for the biological and medical sciences
8. Columbia University Medical Center/NY-Presbyterian experts at AAN
9. CWRU spinoff ConservoCare gets licensing options to develop medical device for bladder control
10. Paving the way for greater use of ancient medical knowledge
11. Sanford-Burnham Medical Research Institute and Mayo Clinic extend collaborative agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: